Cancer News and Research

Latest Cancer News and Research

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

New bone marrow transplantation technique shows prompt immune recovery

Although bone marrow transplants have long been standard for acute leukemia, current treatments still rely on exact matches between donor and patient. Now, scientists at the University of Perugia, Italy, and the Weizmann Institute of Science have improved on a method of transplanting bone marrow-based stem cells from a mismatched donor, making it safer for use when no exact match exists.

8 Dec 2009

BD Diagnostics receives FDA clearance on Amplified DNA Assays

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.

From BD (Becton, Dickinson and Company) 8 Dec 2009

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Seattle Genetics, Inc. today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma.

8 Dec 2009

Non-clinical data of CK-2017357 presented by Cytokinetics

Cytokinetics, Incorporated announced today that both a poster and an oral presentation summarizing non-clinical data regarding CK-2017357, a novel fast skeletal troponin activator, were presented at the 5th Cachexia Conference, organized by the Society on Cachexia and Wasting Disorders, being held December 5-8, 2009 in Barcelona, Spain.

8 Dec 2009

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Celldex Therapeutics to present poster on its first antibody-drug conjugate product

Celldex Therapeutics, Inc. today announced that the Company’s first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium.

8 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

iRGD peptide found to enhance both cancer detection and treatment

Researchers at Burnham Institute for Medical Research at University of California, Santa Barbara have identified a peptide (a chain of amino acids) that specifically recognizes and penetrates cancerous tumors but not normal tissues.

8 Dec 2009

bioMerieux announces the upcoming availability of ABxAlert from ICNet International

bioMerieux, a world leader in the field of in vitro diagnostics, announced the upcoming availability of ABxAlert® from ICNet International Ltd., a global clinical informatics company, at the 44th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition.

8 Dec 2009

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

8 Dec 2009

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

CompuCyte expands iGeneration line of imaging cytometers to include four-laser versions

CompuCyte Corporation, the pioneer in the field of imaging cytometry instrumentation and the leading supplier of laser scanning cytometers, announced that it has expanded its state-of-the art iGeneration line of imaging cytometers to include four-laser versions of the iCyte®, iCys® and iColor® systems.

8 Dec 2009

Phase 1 study results of TRU-016 in patients with CLL announced

BioteTrubion Pharmaceuticals, Inc. and Facet ch Corp. today announced the presentation of positive data from a phase 1 study of TRU-016 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) at the 2009 American Society of Hematology (ASH) Annual Meeting.

8 Dec 2009

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.

7 Dec 2009

Cysteine-rich whey protein supplement may maintain or increase weight in advanced NSCLC patients

Immunotec Inc. announced today the enrollment of the first patient in the US Cancer trial of IMN 1207 being run at Beaumont Hospital's Community Clinical Oncology Program (CCOP) in Royal Oak, Michigan. The goal of the study is to determine the effect of IMN 1207, a cysteine-rich whey protein supplement, in preventing additional weight loss in patients with stage IV (advanced) non-small cell lung cancer.

7 Dec 2009

New data from Allos Therapeutics' FOLOTYN trial for PTCL

Allos Therapeutics, Inc. today reported a new analysis of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

7 Dec 2009

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Keryx Biopharmaceuticals Inc. reported updated efficacy and safety data as well as new survival data on the clinical activity of perifosine (KRX-0401) in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma.

7 Dec 2009

Black women may need different mammogram guidelines

"Many African-American women don't fit the profile of the average American woman who gets breast cancer. For them, putting off the first mammogram until 50 — as recommended by a government task force — could put their life in danger," NPR reports.

7 Dec 2009

Cancer News and Research

Latest Cancer News and Research

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

CAM314 randomized Phase 3 clinical trial results released

New bone marrow transplantation technique shows prompt immune recovery

BD Diagnostics receives FDA clearance on Amplified DNA Assays

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Non-clinical data of CK-2017357 presented by Cytokinetics

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Celldex Therapeutics to present poster on its first antibody-drug conjugate product

Social isolation and stress can raise breast cancer risk

iRGD peptide found to enhance both cancer detection and treatment

bioMerieux announces the upcoming availability of ABxAlert from ICNet International

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

CompuCyte expands iGeneration line of imaging cytometers to include four-laser versions

Phase 1 study results of TRU-016 in patients with CLL announced

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Cysteine-rich whey protein supplement may maintain or increase weight in advanced NSCLC patients

New data from Allos Therapeutics' FOLOTYN trial for PTCL

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Black women may need different mammogram guidelines

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in